Xylem (XYL) EBIT (2010 - 2026)

Xylem's EBIT history runs 17 years deep, the most recent figure standing at $244.0 million for Q1 2026.

• On a quarterly basis, EBIT rose 5.63% year-over-year to $244.0 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 19.88% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 21.21% from the prior year.
• EBIT fell to $244.0 million in Q1 2026 per XYL's latest filing, from $353.0 million in the prior quarter.
• Across five years, EBIT topped out at $353.0 million in Q4 2025 and bottomed at $111.0 million in Q1 2022.
• The 5-year median for EBIT is $211.0 million (2023), against an average of $220.6 million.
• Across the five-year window, EBIT decreased 18.49% in 2023 and soared 112.61% in 2024, its largest moves.
• Year by year, EBIT stood at $197.0 million in 2022, then increased by 7.11% to $211.0 million in 2023, then rose by 26.54% to $267.0 million in 2024, then soared by 32.21% to $353.0 million in 2025, then slumped by 30.88% to $244.0 million in 2026.
• Per Business Quant, the three latest XYL EBIT figures stand at $244.0 million (Q1 2026), $353.0 million (Q4 2025), and $334.0 million (Q3 2025).